Skip to main
BIOA

BIOA Stock Forecast & Price Target

BIOA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Bioage Labs is developing innovative and promising therapeutics targeting the biology of aging to combat metabolic diseases. With a strong financial position and a deep pipeline of candidates, including BGE-102 and BGE-105, the company is well-positioned for success. The recent ZEUS trial results do not significantly impact the overall potential of their NLRP3 inhibitor, and the mission-driven focus on aging and chronic inflammation sets Bioage Labs apart in the biotech industry.

Bears say

Bioage Labs is a clinical-stage biopharmaceutical company with a negative outlook due to its drug selection and competitive market in metabolic diseases, which raises concerns over the success of its financial performance. With increasing competition and unknowns in the effects of its therapeutics on key metrics such as LDL levels, it is uncertain if the company's drug, ziltivekimab, will prove effective in the market and generate significant revenue. Additionally, the company's commercialization strategy may face challenges in saturated therapeutic areas with established players and partnerships.

BIOA has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioAge Labs Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioAge Labs Inc. (BIOA) Forecast

Analysts have given BIOA a Buy based on their latest research and market trends.

According to 8 analysts, BIOA has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioAge Labs Inc. (BIOA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.